OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Still going well - a new chart would look nice - well covering the losses of my oilers

IMO ... this will continue to push upwards, - with a few troughs caused by nervous punters. Am expecting the new re-rating to be @12p. After this OXB need to produce an RNS to present manufacturing predictions and supporting financials etc, before it can continue towards @30p.

After consolidation @30p long term will be primarily driven by revenues and successful drug pipeline. Perhaps beyond 50p as the drug market and economy grows.

Will continue to recycle shares on peaks and troughs up to the above.

DYOR

HAb

Cracking chart.

Up another 10% today.

And climbing - did push 10p - commenced ownership of OXB 14 years ago and have added to quite regularly . Thank you for the chart mitzy - not one of my qualities but I do have patience !! Get in there.

I read this is now a "buy" by IC - but I wonder what they missed when OXB was 2p - giving reckless investors a thumping 6x reward?
Of course there is "risk" and some of the treatments will be less than successful ( as in the past!), but it needs only one good one and we're away to nudge £1 ( some hope?), as they seem to be well-funded with regular income avoiding that other issue for small-Bios ( Dilution !).
I wonder if Oakapples can work out just how much L-T dilution has cost him - (like me), since those early days? . . . . I'd be surprised if my Av. buy-price isn't about 50p.
Ooo-er!

EDIT (30April2015)- I missed Director sale of 85million Jan 2015. - at 5p....how bad was that? - wait a few months and he could have seen double...11p today.
EDIT (27May2015)- I see a Dir. buying 100,000 at 10p - that's £10G-worth, a little below my "Notice-level" of £50k - but good, even so.
EDIT (17Dec2015)- New Chairman Lorenzo- appointed . . . has pharma industry experience with big players.... I suspect this is the NEWS we've need . . along with an Income stream from 3rd party Manufacture for Novatis.... time will tell, but I can see sp rising as he gets to grips with their future . . . . well...Hope, eh?
Loreanz was the cypher code use in WWII along with Enigma.

Into a new year 2016 for OXB, with manufacturing ramping up and new facility starting to earn revenues. Bit of change around in Exec team.

Perhaps OXB is streamlining to make its balance sheet more attractive and focus on manufacturing and delivery to Novartis / markets. Will become a more attractive takeover target as OXB starts to register on large Institutions radar. Once steady delivery of drug pipeline established, expect small step into dividends. Once this happens expect serious SP rerating.

Am Sticking by my long-term predictions of SP @30p - 40p by this time next year 2017.

DYOR
HAb

Is that Hope? I do wonder...
As I see it....new Exec expected early Feb2016 may signal some changes . . . . but changes rarely start immediately and existing contracts are for Manufacture..... good for loose-cash but nothing exciting...although it gives a Seal of Approv of sorts that Novartis is willing to use OXB facilities. However, this is probably only an overspill facility should they get too busy. We still live in Hope of OXB having a decent product themselves - and that is unlikely to be sudden, although yr right, it might create enough for Inst to notice . . . but so far it's been pretty dire.
30-40p Jan 2017 - is that really likely with World Markets having a bad time in general. That's a 5x rise . . . . . . surely nothing today can do that, like hyped-up IPO's of yesteryear....
EDIT (23FEb2016)- Begging-bowl again! Oh deary, I wonder where all that "working capital" will go - they raised money recently for over-the-road Expansion and new pipes, presumably to satisfy Novatis placing an order for their stocks - at a time now it seems the order wasn't big enough/or/ was not covering hardware improvements - I don't know, but if we were misled ( Can I say that?), with that "fundraising" ((I call it Dilution)), then where is this fresh money going?
Looks like sp will fall to 6p ( the Offer-price; DYOR ) - oh dear....
+I can't see a real sp recovery until some GOOD news is ann. and I suspect at present rate that might be 2017 - Deary me!
. . . . Others . . .

Reading the RNS for this (Feb2016) Share-issue at 6.3p - DYOR - I read there is an outstanding borrowing from Oberland - up to USD50m with interest about 9% and rising . . . someone did a good deal there, but I don't recall this being mentioned . . . did I miss it?
So when was the last begging-bowl offered . . . maybe it wasn't so recent as I thought . . . . odd that.
It really worries me that Dir are prepared to sell/risk ( ? ) the shareholders' property, to patch up their inefficiency . . . the move to windrush and elsewhere was previously covered . . . but it seems they forgot the Training and recruitment costs . . . Let's hope they've got new windows and doors nicely painted and secure . . . .
It smacks of carelessness and I really don't think the Shareholders approved this Oberland involvement . . . next thing we'll hear is that O- are taking the Co. private and the sp is 0.01 next to zero.
EDIT (20Sept2016 )-Looks like Begging-Bowl again . . . at 3p (?) - looking at the recent sp fall since AGM and earlier . . . . Oh dear
+ Dirs DOH! . . . . 23 Sept IC says Sell, but at these prices, I might as well hold - New Mgmt doesn't appear to be very Clued-up perhaps? . . . . . . . . Grr.
EDIT (8Nov2016)-prior to US Election Results. sp 3.55 marginally up on Funding price, I notice DrLz has bought almost £20k-worth in 6-Lots.... Not impressive... . It's about time this Co stopped dragging.
EDIT (14Nov2016)-full page in IC "Sell" so I wonder if the Co will get the message? Stop doing "deals" with big pharma -and become One,=Selling yr own products. A modest "orphan-drug" would bring in profits and oil-the-wheels for further selling.
EDIT (12Jan2017)-sp 4p shows there's little "hope" on horiz. . . . Wake-Up!
EDIT (20April2017)- 4.8p ( recent peak 5.5 )...oh dear.
EDIT (11July2017)- 10p now, Novartis deal reissued...Hope- EDIT: but soon fell... Dir buys £20k-worth gives a blip to 8p but regard the CE buys ~£2k5 monthly isn't exactly exciting money. Hope?- Huh! Where are their own Products? You can't make serious money as a jobbing Bio.
EDIT(7Sept2017)- sp in 8p region after July"17 step-change....Market waiting for progress verification, etc.

Bought some @ 8.485p

they are on the move since yesterday, after a large retracement

-

8.95p +0.55p (+6.55%)

doing nicely on plenty of middle size trades

9.05p +0.65 +7.68%

managed to get over 9p and now holding above 50 days MA

DIRECTORS BUYING

Dr Lorenzo Tallarigo -Chairman
Friday 22 September 2017 acquired 29,685 shares @ 8.90p

That's £2500 near enough . . . what's to shout about that?
Let's not forget that over 20 years this business ha fallen from a position of promise potential to being a jobbing factory.... and shares were until v.recently lingering around one tenth of Early-day values. With so much Dilution, the situation may be far worse.... Dare not lookee.
EDIT (13Dec2017)-sp hardly changed (~8p) on RNS today; potential Novartis income... maybe a way off and still uncertain... but Buys/Sells evens.... Thoughts?
EDIT (17Dec2017)- Recent RNS suggests an. income of ~$100m - from one tie-up Drug.... did I read that wrong? sp blipped but hasn't moved much - probably until the Big-Cash is flowing?
EDIT(2018)- some later posties are above. sorry.

Oxford BioMedica to Present at Cantor Fitzgerald Healthcare Conference 2017, New York

Oxford, UK - 25 September 2017: Oxford BioMedica , a leading gene and cell therapy , today announces that Kyriacos Mitrophanous, Chief Scientific Officer, will be presenting at the Cantor Fitzgerald Healthcare Conference in New York on Wednesday 27 September at 16:35 Eastern Time. Stuart Paynter, Chief Financial Officer will also be attending the event.

On the trading front as buyers were paying as much as 9.75p earlier on
the trend has been up on the chart also as share price is holding well abovee 50 days MA,
with all I can see it is still all looking good

Since the beginning of 2018 sp has been in the 12p region..... partly due to their deal in US which is possibly worth "££ots if the Bio gets Regulatory Approval after further dev. That's the way healthcare goes.... Yet it's interesting that a US-Bio is willing to do a deal with what must be OXB's tech... so, it must have fundamental value, IMHO.
If the product is sold in America ( and in Europe, presumably ), the value to OXB will be transforming, as I read it.... Yet the Market has moved only v.slightly -and on the day of the Ann. I recall it went down a few %. Such is Investor demand for "instant Riches" - Ah well . . . . maybe 15p, then 20p . . . who knows?
I'm hoping their Manufacturing position means there won't be any Cash-Calls . . . as this Co. has a reputation for doing precisely that, within weeks of an AGM.
EDIT (14March2018):-sp~12p.... what a difference a week makes! - As soon as my Msg. was posted, we read there is a £20m/11p begging-bowl going the rounds.
Pah! . . . . Didn't they receive the Up-Front money from USA?
The only "bonus" is the March begging-bowl hasn't yet dropped the sp....but I wonder what is supporting it? Usually the sp falls to the Offer-price, (or below!)...but here, the sp rose early 2018....as if the Institutions wanted to spend money. Very Odd... +DYOR.
EDIT(27Apr2018)- Well, almost 12p - hopefully no BB during 2018 after AGM in May .....
EDIT(6May2018)- Oh dear CONsolidation.... 50:1 -DYOR- will this really change anything? shares instantly nearly £7, - which seems silly . . . . OXB isn't in the same league as the Big Boys with Real Turnover, are they? -OR- is this to distance themselves from the 2-pence days? It won't IMHO. It's a CON - since paperwork only adds COST - everything else is the same.... OXB Execs: -Get Selling and the sp will rise without intervention.
EDIT (22May2018)- sp is 15p for no obvious reason . . . Thoughts anyone?
EDIT (24May2018)...sp up 0.5% with trades 9.4m =Buy and 1.4m=Sell, so the Market appears to be Buying.... Could this be the recent deal in US, said to be worth $100m in Royalties.... yet not yet within grasp . . . =OR= does someone know better? . . . . .
EDIT (30May2018)...sp 720p after 50:1 CONsolidation. ....by 14:30 sp drops to 685p...Ooops! - Yet by 31May it's 723p.... was that earlier "drop" a falsie?
EDIT-30th- by end of Trading it's 661p ( Shown as 5% down ).
EDIT (2 June2018)- yet Friday-closing is 694 . . . is this MM's "Shaking the tree"
EDIT (7June2018)-sp 882 after Parkinson Ann, mentioned by cynic and queen2 . . . also the Trades are +ve. Maybe...just maybe this is showing New-OXB is getting there . . . and with these income-anticipations, the sp can only rise - I hope.
EDIT (15June2018)- Well my Theory that CONsolidation NEVER benefits LT-investeors appears to be failing...sp a few pence off £10. that's abt. 50% rise after the 50:1 notional = 720p. I guess Posters here are right - that "potential" is what punters are buying-into. +I just Hope OXB can deliver, with R4 News of Gene-Therapy advances at Kings Col Lon. which never mentioned OXB.
Ho-Ho and my Broker suggested "top-slicing" at 12p ( that's just £6, so I'd have missed the recent +£4 uplift...).
EDIT (21June2018)- up again, now 1050 - doesn't look like jitters are showing...
EDIT (2July2018)- off the high now; despite late June Euro-approval (w. Novatis partner)...There's 3-yr total potential =£100m - Someone's not reacting right?
EDIT (13July2018)-sp 880...so it looks like the sunny days may be over for now. I'll not sell now, although maybe I should have taken the investment out at the £10+ level.... Let's just hope that drug-deal is a good'un...
EDIT (4Jan2019)- 660p doesn't look too good, but no-news does that to a share.
EDIT(25Jan2019)-I read there are more Execs buying (~£25k-worth), Not massive, but helping...
EDIT (18Feb2019)-Oxf Eye Hosp "Gene Th" on TV News, but nothing about their source or any OXB involvement - OXB was active in Macular; but not sure, in 2019....Anyone?

a tasty rns out this morning ......

Oxford BioMedica said it had entered into an exclusive worldwide licensing agreement with Axovant Sciences to develop and commercialisea a gene therapy developed by the company for Parkinson's disease.

The agreement would see Axovant utilise Oxford BioMedica's LentiVector platform.

Under the terms of the agreement, Oxford BioMedica would receive a $30m upfront payment (£22m) including $5m as pre-payment for manufacturing activities related to OXB-102, now renamed, AXO-Lenti-PD.

Oxford BioMedica was also eligible to receive $55m on achievement of development milestones and $757.5m on achievement of regulatory and sales milestones, with 7% to 10% tiered royalties on net sales of AXO-Lenti-PD.

Game changer. Obviously no guarantees but $757m is potentially stratospheric....